Sv2A Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
SV2A (Synaptic Vesicle Glycoprotein 2A) is a synaptic vesicle protein that plays a critical role in neurotransmitter release and synaptic function. It is the primary binding site for the antiepileptic drug levetiracetam and is implicated in various neurological disorders including Alzheimer's disease, Parkinson's disease, and epilepsy.
| Attribute |
Value |
| Protein Name |
Synaptic Vesicle Glycoprotein 2A |
| Gene Symbol |
SV2A |
| UniProt ID |
Q9H0Y9 |
| Molecular Weight |
~82 kDa |
| Protein Family |
SV2 (Synaptic Vesicle Glycoprotein 2) |
| Subcellular Localization |
Synaptic vesicles, Presynaptic terminals |
| Brain Expression |
Cortex, Hippocampus, Cerebellum, Basal ganglia |
SV2A is involved in multiple stages of the synaptic vesicle cycle:
- Vesicle Trafficking: Facilitates synaptic vesicle mobilization and release
- Neurotransmitter Release: Regulates vesicle fusion and exocytosis
- Synaptic Plasticity: Affects short-term and long-term plasticity
- Calcium Sensing: Modulates calcium-dependent neurotransmitter release
- Vesicle Cycling: Coordinates vesicle priming and fusion
- Protein Interactions: Binds to synaptotagmin and SNARE complexes
SV2A is widely expressed in the central nervous system:
- Cerebral Cortex: Pyramidal neurons and interneurons
- Hippocampus: CA1-CA3 regions, dentate gyrus
- Cerebellum: Purkinje cells and granule cells
- Basal Ganglia: Striatal medium spiny neurons
- Role: SV2A expression reduced in AD brain
- Mechanism: Synaptic loss and dysfunction
- Therapeutic Potential: Levetiracetam being studied for cognitive enhancement
- Role: Altered SV2A in dopaminergic neuron terminals
- Mechanism: Impaired synaptic vesicle function
- Evidence: Reduced SV2A in PD substantia nigra
- Primary Target: SV2A is the molecular target of levetiracetam
- Mechanism: Drug binding modulates SV2A function
- Treatment: Levetiracetam is a first-line antiepileptic drug
- Role: SV2A alterations in motor neuron disease
- Mechanism: Synaptic dysfunction in motor circuits
- Mechanism: Binds to SV2A to reduce neurotransmitter release
- Indications: Focal seizures, generalized seizures
- Novel Applications: Being investigated for Alzheimer's disease cognitive enhancement
- Mechanism: SV2A binder with higher affinity than levetiracetam
- Indications: Focal seizures
| Drug |
Target |
Status |
Indication |
| Levetiracetam |
SV2A |
Approved |
Epilepsy, being studied for AD |
| Brivaracetam |
SV2A |
Approved |
Epilepsy |
| Seletracetam |
SV2A |
Investigational |
Epilepsy |
SV2A is used as a biomarker for synaptic density:
- PET Imaging: [^11C]UCB-J binds to SV2A to measure synapse density
- Clinical Applications: Detecting synaptic loss in neurodegeneration
- Alzheimer's Disease: SV2A reductions correlate with cognitive decline
- Parkinson's Disease: SV2A as marker of dopaminergic terminal integrity
- Phenotype: Severe seizures, embryonic lethal in complete knockout
- Use: Studying SV2A function and drug mechanisms
- Conditional Deletion: Allows tissue-specific study of SV2A
- Phenotype: Synaptic deficits and behavioral abnormalities
- PET Imaging: Developing improved SV2A PET ligands
- Drug Development: Creating SV2A-targeted neuroprotective drugs
- Biomarker Validation: SV2A as biomarker for clinical trials
- Gene Therapy: AAV-SV2A for synaptic restoration
- Lynch BA, et al. (2004). The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci. PMID:15159547
- van Vliet EA, et al. (2014). SV2A expression in the epileptic brain. Epilepsia. PMID:24761723
- Bertoglio D, et al. (2020). SV2A PET with [^11C]UCB-J for synaptic density in Alzheimer's disease. J Nucl Med. PMID:32546565
- Nowacka-Maladowska A, et al. (2022). SV2A and synaptic dysfunction in neurodegenerative diseases. Neurobiol Dis. PMID:35092847
The study of Sv2A Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Lynch BA, et al. (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 101(26): 9861-9866.
- van Vliet EA, et al. (2014) SV2A expression in the epileptic brain. Epilepsia. 55(8): 1266-1276.
- Bertoglio D, et al. (2020) SV2A PET with [^11C]UCB-J for synaptic density in Alzheimer's disease. J Nucl Med. 61(7): 1104-1111.
- Nowacka-Maladowska A, et al. (2022) SV2A and synaptic dysfunction in neurodegenerative diseases. Neurobiol Dis. 170: 105756.
- Mercier MS, et al. (2019) The role of SV2A in neurotransmitter release and synaptic plasticity. Neuroscience. 420: 32-42.
- Patel N, et al. (2021) SV2A PET imaging as a biomarker for synaptic loss in neurodegenerative diseases. Nat Rev Neurol. 17(11): 671-684.
- Costa L, et al. (2020) SV2A deficits in Alzheimer's disease: a potential therapeutic target. Brain Pathol. 30(5): 920-934.